Products
Camidanlumab Biosimilar Antibody-Drug Conjugate (CD25) for Research
Pre-Made Camidanlumab biosimilar, Whole mAb ADC, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Camidanlumab Tesirine (ADCT-301) is an antibody drug conjugate (ADC), composed of the human monoclonal antibody, HuMax-TAC, which is directed against human CD25. The antibody is conjugated through a protease cleavable linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-089-1mg | 1mg | |
| GMP-Bios-ab-089-10mg | 10mg | |
| GMP-Bios-ab-089-100mg | 100mg | |
| GMP-Bios-ab-089-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Camidanlumab biosimilar, Whole mAb ADC, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody |
| INN Name | Camidanlumab |
| Target | IL2RA |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | ADC Therapeutics;Genmab |
| Conditions Approved | na |
| Conditions Active | Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours |
| Conditions Discontinued | Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma |
| Development Tech | na |
About target - IL2RA
1. Protein Interleukin-2 receptor subunit alpha
2. Gene IL2RA
3. Organism Homo sapiens (Human)
Function
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
